ZBIO - NASDAQ
Zenas BioPharma, Inc.
$17.40
+1.6%Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
At a Glance
Live SnapshotZenas BioPharma, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Zenas BioPharma, Inc. Income Statement
ZBIO • NASDAQ
| Zenas BioPharma, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
REVENUE | ||||
10M | 5M | 50M | 0.0 | |
GROSS PROFIT | ||||
(56K) | (139.1M) | (0.0) | (61.7M) | |
9.9M | -134.1M | 50M | -61.7M | |
OPERATING INCOME | ||||
(221.4M) | (29.7M) | (87.1M) | (14.5M) | |
(53.3M) | (29.7M) | (17.1M) | (13.5M) | |
(168.1M) | (139.1M) | (60M) | (62.7M) | |
-211.4M | -163.9M | -37.1M | -76.2M | |
PRE-TAX INCOME | ||||
(7.3M) | (0.0) | (0.0) | (0.0) | |
4.8M | 0.0 | 0.0 | 0.0 | |
(0.0) | -139.1M | (10M) | -61.7M | |
-166.4M | 7.3M | 324K | -43.1M | |
-377.8M | -156.6M | -36.8M | -119.3M | |
NET INCOME | ||||
-79K | (429K) | (301K) | (0.0) | |
-377.7M | -157M | -37.1M | -119.3M |
SEC Filings
ZBIO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 26, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 16, 2026 | May 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 16, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 13, 2026 | February 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 05, 2026 | January 05, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 15, 2025 | December 10, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 |
Related Guides
Continue your ZBIO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.